← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Danaher DHR $158B	890	+83	+10%	$42.1B
2	2 Thermo Fisher Scientific TMO $249B	873	+56	+7%	$40.1B
3	3 Novartis NVS $279B	816	+55	+7%	$20.5B
4	4 Agilent Technologies A $49.1B	583	+36	+7%	$15.7B
5	5 Regeneron Pharmaceuticals REGN $80.1B	438	+24	+6%	$21B
6	6 Illumina ILMN $41B	385	+37	+11%	$16.1B
7	7 Revvity RVTY $17B	311	+17	+6%	$4.25B
8	8 Myriad Genetics MYGN $397M	271	+4	+1%	$2.21B
9	9 Charles River Laboratories CRL $14.4B	239	+9	+4%	$2.49B
10	10 Ionis Pharmaceuticals IONS $7.1B	213	+9	+4%	$4.12B
11	11 Alnylam Pharmaceuticals ALNY $30B	169	+5	+3%	$3.57B
12	12 Bruker BRKR $8.47B	165	-6	-4%	$2.24B
13	13 Azenta AZTA $1.63B	139	+9	+7%	$637M
14	14 DELISTED SANGAMO THERAPEUTICS INC SGMO	115	+4	+4%	$642M
15	15 Sarepta Therapeutics SRPT $1.78B	108	-26	-19%	$559M
16	16 Standard BioTools LAB $248M	100	+11	+12%	$945M
17	17 DELISTED bluebird bio BLUE	81	+14	+21%	$378M
18	18 Pacific Biosciences PACB $619M	80	-1	-1%	$197M
19	19 Precigen PGEN $2.64B	78	+8	+11%	$1.88B
20	20 Arrowhead Research ARWR $8.25B	67	+33	+97%	$262M
21	ISEE 21 DELISTED IVERIC bio, Inc. Common Stock ISEE	64	+55	+611%	$595M
22	22 PTC Therapeutics PTCT $4.98B	61	0	0%	$262M
23	23 Fortress Biotech FBIO $63.4M	60	-21	-26%	$30.6M
24	24 Invesco Biotechnology & Genome ETF PBE $421M	60	+9	+18%	$93.9M
25	25 Lineage Cell Therapeutics LCTX $232M	58	+2	+4%	$60.9M